{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-010075","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.320119+00:00","generated_at":"2026-06-25T15:17:28.078232+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta CMO Kanya Rajangam resigns; David Shook named VP Clinical Development","bullets":["Dr. Kanya Rajangam resigns as CMO effective June 5, 2022, to oversee R&D at a private biotech.","Dr. David Shook appointed VP Clinical Development, leading all clinical and regulatory activities.","Shook is a practicing pediatric hematologist/oncologist and early NK cell therapy pioneer.","Nkarta's NKX101 and NKX019 programs continue; expects to submit updated data for a medical meeting in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-010075","json":"https://secwatch.observer/filing/0000950170-22-010075.json","markdown":"https://secwatch.observer/filing/0000950170-22-010075.md","text":"https://secwatch.observer/filing/0000950170-22-010075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/nktx-20220513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:17:28.078232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5b66f7d97","claim":"Dr. David Shook was appointed as Vice President, Clinical Development at Nkarta, Inc..","evidence_excerpt":"On May 16, 2022, the Company issued a press release announcing the resignation of Dr. Rajangam and the appointment of Dr. David Shook as Vice President, Clinical Development.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President, Clinical Development"}],"fact_type":"executive_change"},{"claim_id":"dfdcb22991","claim":"Dr. Kanya Rajangam resigned as Chief Medical Officer at Nkarta, Inc..","evidence_excerpt":"On May 13, 2022, Dr. Kanya Rajangam notified Nkarta, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company to oversee research and development activities at a private biotechnology company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}